1. Home
  2. CVKD vs ADN Comparison

CVKD vs ADN Comparison

Compare CVKD & ADN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CVKD
  • ADN
  • Stock Information
  • Founded
  • CVKD 2022
  • ADN 2006
  • Country
  • CVKD United States
  • ADN United States
  • Employees
  • CVKD N/A
  • ADN N/A
  • Industry
  • CVKD Medicinal Chemicals and Botanical Products
  • ADN Power Generation
  • Sector
  • CVKD Health Care
  • ADN Utilities
  • Exchange
  • CVKD Nasdaq
  • ADN Nasdaq
  • Market Cap
  • CVKD 8.2M
  • ADN 8.6M
  • IPO Year
  • CVKD 2023
  • ADN N/A
  • Fundamental
  • Price
  • CVKD $0.45
  • ADN $3.82
  • Analyst Decision
  • CVKD Strong Buy
  • ADN Hold
  • Analyst Count
  • CVKD 2
  • ADN 1
  • Target Price
  • CVKD $3.50
  • ADN $18.00
  • AVG Volume (30 Days)
  • CVKD 83.0K
  • ADN 21.1K
  • Earning Date
  • CVKD 08-12-2024
  • ADN 07-30-2024
  • Dividend Yield
  • CVKD N/A
  • ADN N/A
  • EPS Growth
  • CVKD N/A
  • ADN N/A
  • EPS
  • CVKD N/A
  • ADN N/A
  • Revenue
  • CVKD N/A
  • ADN $5,310,000.00
  • Revenue This Year
  • CVKD N/A
  • ADN N/A
  • Revenue Next Year
  • CVKD N/A
  • ADN $2,705.94
  • P/E Ratio
  • CVKD N/A
  • ADN N/A
  • Revenue Growth
  • CVKD N/A
  • ADN N/A
  • 52 Week Low
  • CVKD $0.36
  • ADN $2.70
  • 52 Week High
  • CVKD $2.17
  • ADN $30.00
  • Technical
  • Relative Strength Index (RSI)
  • CVKD 45.59
  • ADN 58.95
  • Support Level
  • CVKD $0.43
  • ADN $3.63
  • Resistance Level
  • CVKD $0.49
  • ADN $4.06
  • Average True Range (ATR)
  • CVKD 0.02
  • ADN 0.29
  • MACD
  • CVKD -0.00
  • ADN 0.09
  • Stochastic Oscillator
  • CVKD 21.00
  • ADN 83.70

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.

About ADN Advent Technologies Holdings Inc.

Advent Technologies Holdings Inc is an innovation-driven company in the fuel cell and hydrogen technology space. The company develops, manufactures, and assembles complete fuel cell systems and the critical components that determine the performance of hydrogen fuel cells and other energy systems. It serves automotive; aviation and power generation industries. It generates revenue from the sale of fuel cell systems and the sale of MEAs, membranes, and electrodes for specific applications in the fuel cell and energy storage (flow battery) markets.

Share on Social Networks: